First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115807 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Maeve A Lowery und 19 weiteren Autor:innen. Beteiligte Einrichtung: Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. Electronic address: mlowery@tcd.ie. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Quality of Life, Stomach Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Merck Sharp and Dohme United Kingdom.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. Electronic address: mlowery@tcd.ie.
- Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of…
- University College Hospital, NHS Foundation Trust, London, United Kingdom.
- Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile.
- Harbin Medical University Cancer Hospital, Harbin, China.
Förderung
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
Lowery, M. A., Wyrwicz, L. S., Oh, D. Y., Shiu, K. K., Yañez, P., Bai, Y., Ryu, M. H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Fernández, M. G., Li, J., Çil, T., Cruz, F. M., Qin, S., Guan, Y., Valderrama, A., Bordia, S., & Rha, S. Y. (2025). First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115807
Vancouver
Lowery MA, Wyrwicz LS, Oh DY, Shiu KK, Yañez P, Bai Y, et al. First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115807
BibTeX
@article{Lowery2025,
author = {Lowery, Maeve A and Wyrwicz, Lucjan S and Oh, Do-Youn and Shiu, Kai-Keen and Yañez, Patricio and Bai, Yuxian and Ryu, Min-Hee and Lee, Jeeyun and Rivera, Fernando and Alves, Gustavo Vasconcelos and Garrido, Marcelo and Fernández, Manuel González and Li, Jin and Çil, Timuçin and Cruz, Felipe Melo and Qin, Shukui and Guan, Yanfen and Valderrama, Adriana and Bordia, Sonal and Rha, Sun Young},
title = {First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115807}
}
EUVIMED